TGFB1 and neoplasm: Furthermore, preclinical models have shown that combining CAR T cells with TGF-β inhibitors results in a more favourable immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells, both of which are associated with immunosuppression in tumours [111].